Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine

Trial Profile

A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs Zolmitriptan (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Registrational
  • Acronyms ADAM
  • Sponsors Zosano Pharma
  • Most Recent Events

    • 23 Oct 2018 Results presented in the Zosano Pharma media release.
    • 23 Oct 2018 According to a Zosano Pharma media release, the company today announced that more than 150 evaluable subjects have completed their six month visit in this trial. The company anticipates that their goal of 50 subjects treated for one year will be complete in the first quarter of 2019.
    • 06 Sep 2018 According to a Zosano Pharma media release, results from this study will be presented at the 5th Annual Transdermal & Intradermal Drug Delivery Systems Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top